Welcome to BIOASTER’s transparency portal. As you may have been informed, this portal allows you to learn about the clinical studies promoted by BIOASTER, especially those that use information collected during your care and treatment. For your information, some of these studies may also be conducted in collaboration with other organizations, both hospital-based and non-hospital-based. This work is essential for advancing scientific knowledge in the areas on which BIOASTER focuses (microbiome, vaccines, diagnostics, and infectious diseases). Each project is summarized to provide you with an overview of the research objectives. You also have access to the identity of the person in charge of the study (“principal investigator”).
In accordance with the applicable laws and regulations, in particular Law No. 78-17 of January 6, 1978 as amended (“French Data Protection Act”) and Regulation (EU) 2016/679 of April 27, 2016 (“GDPR”), you have the following rights concerning your personal data processed by BIOASTER:
- Right of Access: You have the right to request access to your personal data and to obtain information about how it is processed.
- Right to Rectification: You can request the rectification of your personal data if it is inaccurate or incomplete.
- Right to Object: You have the right to object, at any time, to the processing of your personal data for reasons related to your situation, as well as to the processing of your data for direct marketing purposes.
- Right to Erasure: You can request the erasure of your personal data under certain conditions, if the data is no longer necessary for the purposes for which it was collected.
- Right to Restriction of Processing: You can request the restriction of processing of your personal data in certain cases, if you contest the accuracy of the data or if the processing is unlawful, without you wishing for its erasure.
If, for any reason, you are unable to exercise your rights in this way, you also have the right to file a complaint about the processing of your personal data to a supervisory authority. The supervisory authority may be the national data protection authority of your country, such us “Commission Nationale Informatique et Libertés” (CNIL) in France.
To exercise these rights, you may contact BIOASTER’s Data Protection Officer:
- By email: privacy@bioaster.org
- By post:
BIOASTER
Service juridique
A l’attention du Délégué à la Protection des Données
40 avenue Tony Garnier
69007 Lyon
ADOVAC Study :
Vaccine
INTERVENTIONAL, MULTICENTER, CASE-CONTROL EPIDEMIOLOGICAL STUDY AIMING TO CONFIRM THE MICROBIOLOGICAL, IMMUNOLOGICAL AND INFLAMMATORY COMPONENTS INVOLVED IN ACNE VULGARIS AND TO IDENTIFY POTENTIAL THERAPEUTIC TARGETS
Start date: 24/01/2020
Status: Completed – (12/05/2021)
Principal investigator: Dr Emilie BATHELIER (Dermscan)
Objective: The objective of this research is to confirm the microbiological components involved in acne as well as the inflammatory and immune responses triggered by the body through the analysis of skin samples from superficial and deep areas. This could contribute to the identification of antigens that could be included in a vaccine against acne.
BACTSEQ Study :
Diagnostics
Evaluation of a molecular technology for the detection of pathogens in blood cultures and the prediction of their antibiotic susceptibility
Start date: 13/01/2021
Status: Completed – (22/02/2023)
Principal investigator: Professor François VANDENESCH, Bacteriology Laboratory, Institute of Infectious Agents – HCL
Objective: The objective of this study is to evaluate a new molecular sequencing tool capable of identifying all microorganisms (bacteria, yeasts, etc.) present in a blood sample and predicting their antibiotic resistance through the exploration of their genomes, without the need for long and tedious culture steps. This tool could improve patient diagnosis and management and could represent a real benefit for patient survival.
COVERT Study :
Diagnostics
Single-center, interventional diagnostic study with minimal risks and constraints, aiming to longitudinally evaluate the level of serum antibodies in patients with COVID-19 according to the severity of their symptoms.
Start date: 25/09/2020
Status: Completed (17/11/2020)
Principal investigator: Dr Mylène MAILLET – Annecy Genevois Hospital Center
Objective: The primary objective of this RIPH2 study is to measure, over a longitudinal study, the humoral response developed by patients with COVID-19 and to define a possible correlation between the level of serum antibodies (IgM/IgG), the stage of the disease (relative to the date of the first symptoms) and the severity of the disease (severe versus moderate form).
BISCOTE Study :
Microbiome
Non-interventional, multicenter study aiming to establish a collection of biological samples collected from centenarians and used for scientific purposes.
Start date: 15/02/2023
Status: Completed (18/10/2023)
Principal investigator: Pr Olivier HANON – Gérond’if, Île-de-France Gerontology Center
Objective: The primary objective is to collect 40 pairs of biological samples (stool/blood) from centenarians, a population of interest to the scientific community in the field of healthy aging. The secondary objective is to establish a biobank of stool and blood samples to be used for scientific purposes. The samples and data thus stored will allow the conduct of scientific studies to develop knowledge on the intestinal microbiota, through the identification, isolation and culture of microbial species of interest (bacteria, fungi, yeasts, viruses) as well as the determination of correlations between the composition of the microbiota and the immune response of individuals.
FIFTY+ Study :
Microbiome
: Characterization of the fecal microbiota of a population aged 50-75 years, targeted by seasonal vaccination – a minimal risk, interventional study aiming to establish a collection of biological samples collected from a population of volunteers aged 50-75 years and used for scientific purposes
Start date: 05/07/2023
Status: Completed (12/12/2023)
Principal investigator: Dr Stéphanie Cavigioli – Biofortis
Objective: The primary objective is to establish a collection of biological samples (stool/blood) collected from a population of 60 subjects aged 50-75 years to be used for scientific purposes in the field of the microbiome and its interactions with the host